Treatment of mixed anxiety and depressive disorder: results from a observational study of the efficacy and tolerability of agomelatine

Objective: to study the efficacy, safety and tolerability of agomelatine in mixed anxiety and depressive disorder.
Patients and methods. Agomelatine was administered to 30 patients diagnosed with mixed anxiety and depressive disorder for 3 months. The patients' condition was assessed using a battery of psychometric methods – the Hamilton Depression Scale, the Hamilton Anxiety Scale, and a short form of the SF-12v2 quality of life questionnaire.
Results and discussion. It was shown that agomelatine effectively reduces both symptoms of depression and anxiety, begins to have a therapeutic effect a week after the start of administration, however, the drug shows the best clinical effect when administered for a period of three months or more. The predictors of complete remission on agomelatine therapy in this sample were: the presence of sleep disorders (early and medium, but not late insomnia), a greater severity of somatized anxiety, the presence of complaints of decreased workplace performance and activity.
Conclusion. Our study has shown that agomelatine is an effective, safe and well-tolerated drug in the treatment of mixed anxiety and depressive disorder.

1. Khoonsari H, Oghazian MB, Kargar M, et al. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients with Mixed AnxietyDepressive Disorder. Iran J Psychiatry Behav Sci. 2015;9(2):e230. doi: 10.17795/ijpbs230

2. Spijker J, Batelaan N, de Graaf R, Cuijpers PJ. Who is MADD? Mixed anxiety depressive disorder in the general population. Affect Disord. 2010;121(1-2):180. doi: 10.1016/j.jad.2009.06.008

3. ЗZabylina NA. Diagnostic issues of mixed anxiety and depressive disorder. Journal of Siberian Medical Sciences. 2008;(4):3 (In Russ.).

4. Neznanov NG, Martynihin IA, Mosolov SN. Diagnosis and treatment of anxiety disorders in Russian Federation. Dnevnik psikhiatra (psikhiatricheskaya gazeta). 2017;(1):18-9 (In Russ.).

5. Syrkin AL, Smulevich AB, Syrkina EA, et al. Psychosomatic syndroms in IHD and their influence on the course of the disease. Kardiologiya i serdechno-sosudistaya khirurgiya. 2019;12(5):395-401 (In Russ.).

6. Romanov DV, Petelin DS, Volel BA. Depression in neurological practice. Meditsinskiy sovet. 2018;(1):38-45. doi: 10.21518/2079-701X-2018-1-38-45 (In Russ.).

7. Volel BA. Valdoxan (agomelatine) – innovative mode of action. Psikhiatriya i psikhofarmakoterapiya. 2008;(3):35-9 (In Russ.).

8. Romanov DV, Volel BA, Petelin DS. Approaches to therapy for depressions in neurology: prospects for the use of agomelatine. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):101-10. doi: 10.14412/2074-2711-2018-4-101-110 In Russ.).

9. Smulevich AB, Andryushhenko AV, Brazhnikov AYu, et al. The efficacy and safety of Valdoxan (agomelatine) in the treatment of depression in interdisciplinary departments of the general medical network (observational program FORUM). Psikhicheskie rasstrojstva v obshhej meditsine. 2014;(2):24-40 (In Russ.).

10. Volel BA. Safety and efficacy of agomelatine in the treatment of anxiety and depressive disorders in clinical practice (based on OCTAVA protocol). Psikhiatriya i psikhofarmakoterapiya. 2015;17(2):9-14 (In Russ.).

11. Avedisova AS, Zaharova KV, Marachev MP. The results of observational studies «JAZZ» – «the efficacy of agomelatine (valdoxan) in the treatment of patients with anxious depression as part of a major depressive disorder». Psikhiatriya i psikhofarmakoterapiya. 2013;15(6):14-22 (In Russ.).

12. Smulevich AB, Ivanov SV. Depression and biological rhythms: questionnaire study CYRCADIAN-I. Psikhiatriya i psikhofarmakoterapiya. 2008;(6):4-8 (In Russ.).

13. Vorobyova OV. Valdoxan in the treatment of depression in neurological practice: results of the Russian multicenternaturalistic study «Resonance». Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2012;112(9):47 (In Russ.).

14. Yahno NN, Voznesenskaya TG. Efficacy and tolerability of agomelatine in treatment of mild and moderate depression in neurology (results of Russian multicenter study «Kamerton»). Nevrologicheskiy zhurnal. 2012;17(1):43-9 (In Russ.).

15. Artemov AN, Vasilenko IV, Trif YuV, et al. Experience of using Valdoxan in the treatment of anxiety-depressive disorders in post-stroke patients in the early recovery period. Psikhicheskie rasstrojstva v obshhej meitsine. 2011;(1):42-5 (In Russ.).

16. De Zwart PL, Jeronimus BF, de Jonge P. Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review. Epidemiol Psychiatr Sci. 2019;28(5):544-62. doi: 10.1017/S2045796018000227

17. Lam RW. The importance of early symptom relief in antidepressant treatment: focus on agomelatine. J Psychopharmacol. 2010;24(2):27-30. doi: 10.1177/1359786810372979

18. Wang SM, Woo YS, Kim NY, et al. Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis. Clin Psychopharmacol Neurosci. 2020;18(3):423-33. doi: 10.9758/cpn.2020.18.3.423

19. Guardiola-Lemaitre B, De Bodinat C, Delagrange P, et al. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171(15):3604-19. doi: 10.1111/bph.12720

20. Tabeeva GR, Sergeev AV, Gromova SA, Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2c-receptor antagonist agomelatin (valdoxan). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2011;111(9):32-6 (In Russ.).